Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €251.93 EUR
Change Today +0.31 / 0.12%
Volume 10.7K
RHO5 On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 2:22 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHO5) Snapshot

Open
€251.75
Previous Close
€251.62
Day High
€255.39
Day Low
€250.00
52 Week High
03/24/15 - €261.80
52 Week Low
04/11/14 - €203.70
Market Cap
216.3B
Average Volume 10 Days
16.2K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/5/15
P/E TM
--
Dividend
€7.81
Dividend Yield
2.96%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHO5)

roche holding ag-genusschein (RHO5) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holding ag-genusschein (RHO5) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holding ag-genusschein (RHO5) Key Developments

Sigma-Aldrich Corporation Announces Exclusive Distribution Agreement with Roche

Sigma-Aldrich Corporation announced it signed an exclusive global distribution agreement with Roche. The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the eCommerce and supply chain capabilities of Sigma-Aldrich. Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications.

Celldex Therapeutics Enters into Clinical Trial Collaboration with Roche Holding to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Renal Cell Carcinoma Treatment

Celldex Therapeutics has entered into a clinical trial collaboration with Roche Holding to evaluate the safety, tolerability and preliminary efficacy of a renal cell carcinoma treatment. The clinical trial will test varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies designed to use the body's own immune system to fight cancer through separate but complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.

Roche Announces USD 91 Million Investment in Brazil to Consolidate Position Across Latin America

Roche announced that it would invest BRL 300 million (USD 91 million) over the next five years in its facility in Rio de Janeiro, Brazil. The investment will help modernise the facility to transform it into a Latin American hub to export pharmaceutical products across the region. The announcement was made by Roche's representative in Brazil Christoph Franz, who stated that in comparison with other emerging markets Brazil has been growing faster for the Swiss company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO5:GR €251.93 EUR +0.31

RHO5 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $303.56 USD +2.24
Bayer AG €139.61 EUR +0.422
Gilead Sciences Inc $101.00 USD -0.075
Pfizer Inc $34.53 USD +0.37
Sanofi €91.69 EUR +0.31
View Industry Companies
 

Industry Analysis

RHO5

Industry Average

Valuation RHO5 Industry Range
Price/Earnings 25.2x
Price/Sales 4.6x
Price/Book 11.8x
Price/Cash Flow 20.5x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.